CN108603232A - 监测骨髓瘤的治疗或进展 - Google Patents

监测骨髓瘤的治疗或进展 Download PDF

Info

Publication number
CN108603232A
CN108603232A CN201680070973.XA CN201680070973A CN108603232A CN 108603232 A CN108603232 A CN 108603232A CN 201680070973 A CN201680070973 A CN 201680070973A CN 108603232 A CN108603232 A CN 108603232A
Authority
CN
China
Prior art keywords
individual
nucleic acid
mutation
kras
nras
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680070973.XA
Other languages
English (en)
Chinese (zh)
Inventor
A.斯潘塞
S.米思拉普拉布
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015905013A external-priority patent/AU2015905013A0/en
Application filed by Individual filed Critical Individual
Publication of CN108603232A publication Critical patent/CN108603232A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
CN201680070973.XA 2015-12-03 2016-12-02 监测骨髓瘤的治疗或进展 Pending CN108603232A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2015905013 2015-12-03
AU2015905013A AU2015905013A0 (en) 2015-12-03 Monitoring treatment or progression of myeloma
AU2016903019 2016-08-01
AU2016903019A AU2016903019A0 (en) 2016-08-01 Monitoring treatment or progression of myeloma (2)
PCT/AU2016/051191 WO2017091865A1 (en) 2015-12-03 2016-12-02 Monitoring treatment or progression of myeloma

Publications (1)

Publication Number Publication Date
CN108603232A true CN108603232A (zh) 2018-09-28

Family

ID=58796005

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680070973.XA Pending CN108603232A (zh) 2015-12-03 2016-12-02 监测骨髓瘤的治疗或进展

Country Status (8)

Country Link
US (1) US20180282820A1 (enExample)
EP (1) EP3384050A4 (enExample)
JP (2) JP2018537128A (enExample)
KR (1) KR20180088690A (enExample)
CN (1) CN108603232A (enExample)
AU (1) AU2016363113A1 (enExample)
CA (1) CA3007426A1 (enExample)
WO (1) WO2017091865A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112698037A (zh) * 2021-03-25 2021-04-23 北京积水潭医院 一种检测多发性骨髓瘤治疗效果的抗体组合物及其试剂盒和应用
CN112760290A (zh) * 2019-10-21 2021-05-07 郑州大学 携带突变的肿瘤驱动基因的干细胞及其用途
CN113874525A (zh) * 2018-10-29 2021-12-31 分子听诊器公司 使用无细胞信使rna的骨髓表征
CN114072546A (zh) * 2018-10-30 2022-02-18 分子听诊器公司 无细胞rna文库制备

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11322224B2 (en) 2010-05-18 2022-05-03 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US12221653B2 (en) 2010-05-18 2025-02-11 Natera, Inc. Methods for simultaneous amplification of target loci
US20190010543A1 (en) 2010-05-18 2019-01-10 Natera, Inc. Methods for simultaneous amplification of target loci
US10316362B2 (en) 2010-05-18 2019-06-11 Natera, Inc. Methods for simultaneous amplification of target loci
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
US9677118B2 (en) 2014-04-21 2017-06-13 Natera, Inc. Methods for simultaneous amplification of target loci
US12152275B2 (en) 2010-05-18 2024-11-26 Natera, Inc. Methods for non-invasive prenatal ploidy calling
BR112013020220B1 (pt) 2011-02-09 2020-03-17 Natera, Inc. Método para determinar o estado de ploidia de um cromossomo em um feto em gestação
US20140100126A1 (en) 2012-08-17 2014-04-10 Natera, Inc. Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data
US20180173846A1 (en) 2014-06-05 2018-06-21 Natera, Inc. Systems and Methods for Detection of Aneuploidy
US11479812B2 (en) 2015-05-11 2022-10-25 Natera, Inc. Methods and compositions for determining ploidy
RU2760913C2 (ru) 2016-04-15 2021-12-01 Натера, Инк. Способы выявления рака легкого
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
GB201618485D0 (en) 2016-11-02 2016-12-14 Ucl Business Plc Method of detecting tumour recurrence
WO2018134254A1 (en) 2017-01-17 2018-07-26 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CA3067637A1 (en) 2017-06-20 2018-12-27 The Medical College Of Wisconsin, Inc. Assessing transplant complication risk with total cell-free dna
US11810672B2 (en) 2017-10-12 2023-11-07 Nantomics, Llc Cancer score for assessment and response prediction from biological fluids
CN107881233A (zh) * 2017-10-31 2018-04-06 天津协和华美医学诊断技术有限公司 一种检测骨髓瘤相关基因群的检测试剂盒
US12084720B2 (en) 2017-12-14 2024-09-10 Natera, Inc. Assessing graft suitability for transplantation
US12024738B2 (en) 2018-04-14 2024-07-02 Natera, Inc. Methods for cancer detection and monitoring
EP3784805A1 (en) * 2018-04-23 2021-03-03 Inivata Limited Method for predicting and monitoring response to an immune checkpoint inhibitor
US12234509B2 (en) 2018-07-03 2025-02-25 Natera, Inc. Methods for detection of donor-derived cell-free DNA
BR112021002189A2 (pt) 2018-08-08 2021-05-04 Inivata Ltd. método de sequenciamento que usa pcr multiplex de replicação variável
WO2020131955A1 (en) * 2018-12-17 2020-06-25 The Medical College Of Wisconsin, Inc. Assessing risk with total cell-free dna
US11931674B2 (en) 2019-04-04 2024-03-19 Natera, Inc. Materials and methods for processing blood samples
US20210087638A1 (en) * 2019-09-23 2021-03-25 Dana-Farber Cancer Institute, Inc. Next-generation sequencing assay for genomic characterization and minimal residual disease detection in the bone marrow, peripheral blood, and urine of multiple myeloma and smoldering myeloma patients
EP4055187B1 (en) * 2019-11-06 2025-08-20 The Board of Trustees of the Leland Stanford Junior University Methods for analyzing nucleic acid molecules
FR3105738B1 (fr) * 2019-12-26 2024-01-05 P M B Dispositif d’irradiation collaboratif
CN116679065B (zh) * 2023-07-31 2023-11-14 北京大学人民医院 检测试剂的应用、多发性骨髓瘤治疗预后预测方法及产品

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102149401A (zh) * 2008-08-12 2011-08-10 俄亥俄州立大学研究基金会 用于多发性骨髓瘤的诊断、预后和治疗的基于微rna的组合物和方法
CN102713606A (zh) * 2009-11-13 2012-10-03 无限制药股份有限公司 用于鉴定、评估、预防和治疗癌症的组合物、试剂盒和方法
WO2014151117A1 (en) * 2013-03-15 2014-09-25 The Board Of Trustees Of The Leland Stanford Junior University Identification and use of circulating nucleic acid tumor markers
WO2015058176A1 (en) * 2013-10-19 2015-04-23 Trovagene, Inc. Detecting mutations in disease over time

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150184246A1 (en) * 2011-11-11 2015-07-02 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102149401A (zh) * 2008-08-12 2011-08-10 俄亥俄州立大学研究基金会 用于多发性骨髓瘤的诊断、预后和治疗的基于微rna的组合物和方法
CN102713606A (zh) * 2009-11-13 2012-10-03 无限制药股份有限公司 用于鉴定、评估、预防和治疗癌症的组合物、试剂盒和方法
WO2014151117A1 (en) * 2013-03-15 2014-09-25 The Board Of Trustees Of The Leland Stanford Junior University Identification and use of circulating nucleic acid tumor markers
WO2015058176A1 (en) * 2013-10-19 2015-04-23 Trovagene, Inc. Detecting mutations in disease over time

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ELIZABETH O DONNELL等: "Clinical Grade "SNaPshot" Genetic Mutation Profiling in Multiple Myeloma", 《EBIOMEDICINE》 *
GIADA BIANCHI和IRENE M. GHOBRIAL: "Biological and Clinical Implications of Clonal Heterogeneity and Clonal Evolution in Multiple Myeloma", 《CURR CANCER THER REV》 *
R. KAEDBEY等: "Noninvasive diagnosis of actionable mutations by deep sequencing of circulating cell free DNA (cfDNA) in multiple myeloma (MM)", 《106TH ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-CANCER-RESEARCH》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113874525A (zh) * 2018-10-29 2021-12-31 分子听诊器公司 使用无细胞信使rna的骨髓表征
CN114072546A (zh) * 2018-10-30 2022-02-18 分子听诊器公司 无细胞rna文库制备
CN112760290A (zh) * 2019-10-21 2021-05-07 郑州大学 携带突变的肿瘤驱动基因的干细胞及其用途
CN112698037A (zh) * 2021-03-25 2021-04-23 北京积水潭医院 一种检测多发性骨髓瘤治疗效果的抗体组合物及其试剂盒和应用

Also Published As

Publication number Publication date
AU2016363113A1 (en) 2018-06-07
WO2017091865A1 (en) 2017-06-08
JP2018537128A (ja) 2018-12-20
KR20180088690A (ko) 2018-08-06
CA3007426A1 (en) 2017-06-08
EP3384050A1 (en) 2018-10-10
EP3384050A4 (en) 2019-07-31
US20180282820A1 (en) 2018-10-04
JP2022000059A (ja) 2022-01-04

Similar Documents

Publication Publication Date Title
CN108603232A (zh) 监测骨髓瘤的治疗或进展
US11613786B2 (en) Clonal haematopoiesis
JP7573443B2 (ja) 循環腫瘍ｄｎａの個別化された検出を用いる癌検出およびモニタリングの方法
JP6700333B2 (ja) ヘテロ接合性の消失（ｌｏｓｓ ｏｆ ｈｅｔｅｒｏｚｙｇｏｓｉｔｙ）を評価するための方法および材料
US20220056534A1 (en) Methods for analysis of circulating cells
CN106715723A (zh) 测定样品中pik3ca突变状态的方法
WO2016134136A2 (en) Genomic alterations in the tumor and circulation of pancreatic cancer patients
JP2022173308A (ja) エンザスタウリンの活性を予測するための方法および組成物
CN107949642A (zh) 用于筛选实体瘤的组合物和方法
JP7665659B2 (ja) 循環腫瘍核酸分子のマルチモーダル分析
WO2017112738A1 (en) Methods for measuring microsatellite instability
US20230002831A1 (en) Methods and compositions for analyses of cancer
US20190161808A1 (en) Method for predicting prognosis of breast cancer patients by using gene deletions
CN120435568A (zh) 用于确定微卫星不稳定性状态的方法、试剂盒及其用途
JP2025521123A (ja) がん治療モニタリングのためのシステムおよび方法
WO2017106365A1 (en) Methods for measuring mutation load
US20230250482A1 (en) Method of detecting and quantifying geonomic and gene expression alterations using rna
RU2811503C2 (ru) Способы выявления и мониторинга рака путем персонализированного выявления циркулирующей опухолевой днк
WO2025228816A1 (en) Method of targeted sequencing for diagnosis
EA050254B1 (ru) Быстрое обнаружение анеуплоидии

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180928